Akoya Biosciences, Inc. (AKYA)
NASDAQ: AKYA · Real-Time Price · USD
1.220
-0.050 (-3.94%)
At close: May 28, 2025, 4:00 PM
1.220
0.00 (0.00%)
After-hours: May 28, 2025, 4:54 PM EDT
Akoya Biosciences Revenue
Akoya Biosciences had revenue of $16.64M in the quarter ending March 31, 2025, a decrease of -9.32%. This brings the company's revenue in the last twelve months to $79.96M, down -14.55% year-over-year. In the year 2024, Akoya Biosciences had annual revenue of $81.67M, down -15.48%.
Revenue (ttm)
$79.96M
Revenue Growth
-14.55%
P/S Ratio
0.79
Revenue / Employee
$390,054
Employees
205
Market Cap
60.85M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
AKYA News
- 5 days ago - Kent Lake Responds to Quanterix's Post-Effective Amendment and Akoya's Superior $1.40-per-Share Alternative Proposal - PRNewsWire
- 16 days ago - Akoya Biosciences Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 21 days ago - AKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYA - Business Wire
- 4 weeks ago - Kent Lake Issues Statement on Quanterix's Blatant Disregard for Will of Shareholders - Business Wire
- 4 weeks ago - Quanterix and Akoya Biosciences Announce Amended Merger Agreement - Business Wire
- 4 weeks ago - Akoya Biosciences and Enable Medicine Launch the Largest Commercially Available Single-Cell Spatial Proteomics Atlas - GlobeNewsWire
- 4 weeks ago - Akoya Biosciences Expands Biopharma Service Portfolio with New ADC Breast Cancer Assay and Real-world IO60 Insights at AACR 2025 - GlobeNewsWire
- 5 weeks ago - Akoya Biosciences and Singapore Translational Cancer Consortium (STCC) Partner on SUPER Study Designed to Advance Cancer Immunophenotyping for Patients in Singapore - GlobeNewsWire